Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

Now that mRNA-based vaccines and gene therapies have been proven, how do we as an industry take the next step? How do we produce the large quantities of high-quality viral vectors and plasmids needed to propel other candidates forward? 

Innovation has a key role to play. Here we’ll describe modern purification technology for plasmid DNA and adeno-associated virus (AAV) that’s poised to improve productivity and speed in both processes. We’ll compare this new tech with legacy methods to show what’s possible.

In this webinar, you will learn about:

• Strategies to increase capacity and flexibility in plasmid production.  
• Optimizing plasmid transfection-based production of AAV in suspension culture using single-use bioreactors.
• Implementing scalable and robust technologies based on filtration and chromatography for efficient purification of biologically active AAV.
• Novel Fibro chromatography for plasmid purification and AAV capture.

Mats Lundgren

Customer Applications Director, Life Sciences, Cytiva

Mats has more than 25 years of experience in the field of biotechnology. He holds a PhD in Immunology, Cell and Molecular Biology from the Karolinska Institute, Stockholm, Sweden and extensive post-doc training at the MRC Clinical Sciences Centre, Imperial College School of Medicine in London, UK. In his industrial career Mats has had positions as scientist, team manager and Vice President at Pharmacia, AstraZeneca and smaller biotech companies.  In his previous function, Mats was managing both the Cell line and Upstream Process Development teams at a major biotech company.  In his current role, Mats works across different viral vector and vaccine application projects as well as general upstream topics, focusing on customer support, applicability of new technologies and manufacturing solutions.

Peter Guterstam

Product Manager, Next Generation Resins & Technologies, Cytiva

Peter is Global Product Manager at Cytiva with responsibility for products tailored for downstream processing of Advanced Therapy Medicinal Products. He is based in Uppsala, Sweden. Peter earned is PhD in Neurochemistry from Stockholm University in 2009. He has been with GE since 2003, primarily working in various roles associated with oligonucleotide synthesis and purification. Since GE’s acquisition of Puridify, Peter has the business responsibility to develop products based on the Fibro technology to complement Cytiva’s portfolio of chromatography resins and to develop it further to generate tailored solutions for the manufacture of Advanced Therapy Medicinal Products.

Henrik Ihre

Director Strategic Technologies, Cytiva

Henrik Ihre has his roots in biopharma, leadership and product development for the biopharma downstream industry in specific. He is motivated by bringing new solutions and manufacturing of new pharmaceuticals for patients developed by partners of Cytiva. He has been the Director of Strategic Technologies since March 2020 with specific knowledge and background in the downstream purification of biopharmaceuticals for over 20 years. 

Watch now

SPEAKERS

Mats Lundgren

Customer Applications Director, Life Sciences, Cytiva

Peter Guterstam

Product Manager, Next Generation Resins & Technologies, Cytiva

Henrik Ihre

Director Strategic Technologies, Cytiva

You might also like

Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering

Lisa Prendergast

19 March

Watch

Expediting development and manufacture of advanced therapies: critical starting materials case study

Andrew Frazer

21 February

Watch

Considerations to optimize and act upon long-term follow-up studies for cell and gene therapies

K Wonnacott, L Pelloso, D Takefman et al.

11 April

Watch

Optimizing bioprocess purification: effective nucleic acid removal in high salt environments

Joanna Niska-Blakie, Eleonora Turco

22 August

Watch

Discover the road to success for viral vector production: strategies, insights, and regulatory considerations

S Shore, A Gilbert, J Bishop

20 June

Watch